- Recursion to Participate in Upcoming Investor Conferences
- Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
- Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
- Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
- Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
- Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9
- Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program
- Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
- Recursion to Participate in Upcoming Investor Conference
- Recursion Publishes Annual Environmental, Social and Governance Report
More ▼
Key statistics
On Monday, Recursion Pharmaceuticals Inc (RXRX:NSQ) closed at 8.59, 72.84% above the 52 week low of 4.97 set on Nov 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.39 |
---|---|
High | 8.86 |
Low | 8.32 |
Bid | 8.53 |
Offer | 8.60 |
Previous close | 8.59 |
Average volume | 4.51m |
---|---|
Shares outstanding | 237.66m |
Free float | 218.35m |
P/E (TTM) | -- |
Market cap | 1.97bn USD |
EPS (TTM) | -1.62 USD |
Data delayed at least 15 minutes, as of Jun 03 2024 21:00 BST.
More ▼